gavel-istock-509557490-brianajackson

brianajackson / iStockphoto.com

9 June 2017Americas

PTAB awards victory to Bass in Diprivan IPR

The Patent Trial and Appeal Board (PTAB) has handed victory to hedge fund manager Kyle Bass in an inter partes review (IPR) against a European healthcare company Fresenius Kabi-owned patent.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?